Exelixis, Inc.
Status: Publicly traded
Direct answer
Exelixis, Inc. is publicly traded on NASDAQ under the ticker EXEL.
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ...
Can you invest in Exelixis, Inc.?
Yes. Exelixis, Inc. trades publicly on NASDAQ as EXEL.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Exelixis, Inc.
Detailed equity research is provided by MarketSnap.